STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Discover expert insights from Dr. Punam Krishan as she debunks common myths about obesity and explains why it is a medical condition, not just a lifestyle choice.

According to the NHS, a BMI (Body Mass Index) between 25 and 30 is classified as overweight, and anything over 30 is considered obese. By this measure, it's estimated that a quarter of all UK adults are living with obesity.

Despite these facts, myths about obesity and its causes persist. A new survey from Yazen Health, providing a digital health care for medically assisted weight loss, reveals that over a third of Brits (37%) believe obesity is a lifestyle choice rather than a disease. They cite motivation (45%), laziness (43%), personal choice (33%), and genetics (33%) as the main barriers to maintaining a healthy weight.

We encourage patients to listen to expert advice and understand that obesity is a complex condition. Dr. Punam Krishan, speaking with Aston, emphasises that obesity is not just a matter of personal choice but a medical condition requiring proper care and treatment.

At Yazen Health, we are dedicated to providing the support and resources needed to address weight issues safely and effectively.

Let us help you on your journey to better health and well-being.

Listen to the radio podcast here. https://www.gateway978.com/blogs/daytime/dr-punam-krishan-debunking-myths-surrounding-obesity

Start your weight loss journey with Yazen today

Everything you need to do is to create an account and answer some questions about your health

Get Started
Get Started
Get Started

More news

Press release
Yazen Health closes €19.5M series A to drive global growth

Yazen Health has successfully closed an oversubscribed €19.5 million series A funding round to fuel its international expansion. This investment enables Yazen to enhance its pioneering obesity treatment model, combining modern weight loss medication with comprehensive lifestyle support.

News
Sifted UK: Yazen raises €19.5m to expand obesity treatment in the EU

Yazen has secured €19.5 million in Series A funding to expand its GLP-1-based obesity treatment across Europe. The company combines medication with lifestyle support for sustainable weight loss results.

News
Lasker~DeBakey Award 2024 for groundbreaking GLP-1 obesity research

Lasker~DeBakey Award 2024 for groundbreaking GLP-1 obesity research